```html

Quarantined Tuberculosis (Multidrug‑Resistant TB)

Overview

Tuberculosis (TB) is an airborne infection caused by the bacterium Mycobacterium tuberculosis. When the strain is resistant to at least isoniazid (INH) and rifampicin—the two most potent first‑line drugs—it is classified as multidrug‑resistant TB (MDR‑TB). “Quarantined” MDR‑TB refers to cases that require strict isolation (often in a health‑care setting or a specially designed home quarantine) to prevent transmission because the organism is highly contagious and treatment options are limited.

MDR‑TB accounts for about 3–4% of new TB cases worldwide and 18% of previously treated cases (World Health Organization, 2023). In the United States, the CDC reports roughly 9,000 new TB cases annually, of which < 0.5% are MDR‑TB. The disease can affect anyone, but certain populations bear a disproportionate burden:

• People living in or traveling from high‑prevalence regions (e.g., India, China, Russia, South Africa).
• Individuals with compromised immune systems, especially HIV‑positive patients.
• Those with a history of incomplete or incorrect TB treatment.
• Close contacts of someone with MDR‑TB, particularly household members.

Because the bacteria are resistant to standard therapy, the infection persists longer and is more likely to spread, making quarantine a critical public‑health measure.

Symptoms

Symptoms of MDR‑TB are identical to drug‑sensitive TB, but they may develop more slowly and can be more severe if treatment is delayed.

• Persistent cough (lasting >3 weeks) – may be dry or produce sputum, sometimes bloody.
• Fever – low‑grade, often worse in the evenings.
• Night sweats – soaking the bedsheets.
• Weight loss – “consumption”‑type weight loss despite normal eating.
• Fatigue and weakness – general sense of being unwell.
• Chest pain – especially when coughing or breathing deeply.
• Shortness of breath – if the disease spreads to lung tissue causing extensive damage.
• Hemoptysis – coughing up blood, a sign of advanced lung involvement.
• Generalized lymphadenopathy – swollen lymph nodes, common in extrapulmonary TB.
• Extrapulmonary manifestations – TB can affect the spine (Pott disease), kidneys, meninges, or other organs; symptoms vary accordingly (e.g., back pain, urinary symptoms, neurological deficits).

Causes and Risk Factors

What causes MDR‑TB?

MDR‑TB arises when the bacteria acquire genetic mutations that render them resistant to first‑line drugs. The most common mechanisms are:

• Spontaneous mutations in the bacterial DNA that affect drug targets (e.g., katG gene for isoniazid resistance).
• Selection pressure from incomplete, irregular, or inappropriate therapy—patients who stop taking medication early give the bacteria a chance to adapt.

Who is at increased risk?

• Previous TB treatment – especially if it was incomplete or supervised poorly.
• HIV infection – weakened immunity makes both acquisition and progression more likely.
• Close contact with a known MDR‑TB case – especially in crowded or poorly ventilated settings.
• Substance use disorders – alcohol, illicit drugs, and smoking can impair immune response and adherence to therapy.
• Socio‑economic factors – poverty, homelessness, and limited access to health care increase exposure and reduce treatment compliance.
• Healthcare workers – repeated exposure to infectious patients.

Diagnosis

Accurate and timely diagnosis is essential both for patient outcomes and for public‑health containment.

Clinical evaluation

• Detailed history (travel, previous TB treatment, contact with TB patients).
• Physical exam focusing on lungs, lymph nodes, spine, and neurologic status.

Laboratory and radiologic tests

• Sputum smear microscopy – detects acid‑fast bacilli (AFB) but does not indicate resistance.
• Culture – gold standard; growth on solid or liquid media takes 2–6 weeks.
• Rapid molecular tests (e.g., GeneXpert MTB/RIF, line‑probe assays) – identify TB DNA and common resistance mutations within hours to days.
• Drug‑susceptibility testing (DST) – performed on cultured isolates to confirm resistance to INH, rifampicin, and second‑line drugs.
• Chest radiography – shows infiltrates, cavitations, or fibrosis typical of pulmonary TB.
• CT scan or MRI – used when extrapulmonary disease is suspected (e.g., spinal or CNS involvement).
• Interferon‑γ release assays (IGRAs) or tuberculin skin test (TST) – indicate prior infection but cannot differentiate drug resistance.

Public‑health measures

When MDR‑TB is suspected, infection‑control teams coordinate isolation, contact tracing, and notification to local health departments (CDC, 2022).

Treatment Options

Because the bacteria are resistant to first‑line drugs, therapy relies on second‑line agents, which are less effective, more toxic, and require longer durations (often 18–24 months).

Medications

Drug Class	Examples	Typical Role in Regimen
Fluoroquinolones	Levofloxacin, Moxifloxacin	Core drug; 6–12 months
Injectable aminoglycosides	Amikacin, Kanamycin, Capreomycin	Intensive phase (first 6–8 months); watch for ototoxicity
Ethionamide / Prothionamide	Ethionamide	Often combined with fluoroquinolone
Cycloserine	Cycloserine	Adds bactericidal activity; neuropsychiatric monitoring needed
Para‑aminosalicylic acid (PAS)	PAS	Adjunct; gastrointestinal side effects common
Linezolid	Linezolid	Highly effective but costly; risk of myelosuppression
Bedaquiline	Bedaquiline	Newer drug; limited to 6 months, cardiac monitoring required
Delamanid	Delamanid	Alternative to bedaquiline; monitor ECG

Regimens are individualized based on DST results, patient tolerance, and drug‑interaction profiles. Directly observed therapy (DOT) or video‑observed therapy (VOT) is strongly recommended to ensure adherence.

Procedures and supportive care

• Surgical resection – rare; considered for localized disease unresponsive to drugs (e.g., cavitary lesions with massive hemoptysis).
• Therapeutic bronchoscopy – to clear obstructing secretions in severe airway involvement.
• Nutritional support – high‑calorie, high‑protein diet to counteract cachexia.
• Management of comorbidities – optimal HIV therapy, diabetes control, smoking cessation.

Lifestyle adjustments

• Strict adherence to medication schedule.
• Isolation until sputum conversion is confirmed on three consecutive monthly cultures (usually 2‑3 months after effective therapy).
• Avoiding alcohol and recreational drugs that worsen liver toxicity.
• Regular exercise within tolerance to maintain lung function.

Living with Quarantined Tuberculosis (multidrug‑resistant TB)

Living under quarantine is challenging, but a structured routine can improve outcomes and mental health.

Daily Management Tips

1. Medication calendar – use a pillbox, phone alarms, or a treatment partner to track doses.
2. Ventilation – keep the quarantine room well‑ventilated (open windows, use HEPA filters if possible) to reduce aerosol concentration.
3. Infection‑control practices – wear a surgical mask when leaving the room for medical visits, cover coughs with a tissue or elbow, and dispose of waste safely.
4. Nutrition – aim for 2,200–2,500 kcal/day with lean protein, whole grains, fruits, and vegetables. Vitamin D and B‑complex supplements may be beneficial (consult your clinician).
5. Hydration – at least 2 L of water daily to thin sputum.
6. Physical activity – light indoor walking or stretching 15–30 min daily; avoid strenuous exertion until cleared by your physician.
7. Psychological support – schedule regular virtual check‑ins with a counselor, join online support groups for MDR‑TB patients, practice mindfulness or breathing exercises.
8. Adverse‑effect monitoring – keep a log of side effects (e.g., hearing changes, vision problems, neuropathy) and report them promptly.
9. Follow‑up appointments – attend all scheduled sputum cultures, blood tests, and imaging studies; late visits can delay detection of treatment failure.

Prevention

• Vaccination – BCG vaccine offers limited protection against pulmonary TB but can prevent severe forms in children (WHO, 2022).
• Early detection and complete treatment – the single most effective way to prevent MDR‑TB is ensuring that drug‑sensitive TB is treated correctly.
• Infection‑control measures in health‑care settings – negative‑pressure rooms, N95 respirators, and rapid molecular testing for all suspected cases.
• Contact tracing and prophylaxis – close contacts should be screened with IGRA/TST; those with latent infection may receive preventive therapy (e.g., fluoroquinolone‑based regimens) under specialist supervision.
• Public‑health education – community outreach in high‑risk areas to promote cough etiquette, ventilation, and early medical evaluation.

Complications

If MDR‑TB is not adequately treated, the infection can cause irreversible damage and life‑threatening conditions:

• Extensive lung destruction – cavitation, fibrosis, chronic respiratory failure, and bronchiectasis.
• Hemoptysis – massive bleeding from eroded blood vessels.
• Spread to other organs – meningitis, pericarditis, osteomyelitis (especially spinal), genitourinary disease.
• Drug toxicity – hearing loss (aminoglycosides), peripheral neuropathy (linezolid), QT prolongation (bedaquiline, delamanid).
• Psychiatric effects – depression, anxiety, or psychosis secondary to cycloserine or disease stigma.
• Increased mortality – Global TB Report 2023 estimates MDR‑TB cure rates around 57% versus 85% for drug‑sensitive TB.

When to Seek Emergency Care

References

• World Health Organization. Global Tuberculosis Report 2023. 2023.
• Centers for Disease Control and Prevention. Multidrug-Resistant TB (MDR TB). Updated 2022.
• Mayo Clinic. Tuberculosis (TB) – Symptoms & causes. Accessed May 2026.
• Cleveland Clinic. Multidrug-Resistant Tuberculosis. Reviewed 2024.
• National Institutes of Health, National Institute of Allergy and Infectious Diseases. Tuberculosis (TB). 2024.
• American Thoracic Society & CDC. Clinical Practice Guidelines for Drug‑Susceptible and Drug‑Resistant TB. 2023.

```